A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Mellitus
Latest Information Update: 13 May 2022
At a glance
- Drugs MK 0893 (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 18 Dec 2013 New trial record